[Read the Letter to the Editor here](http://www.jchimp.net/index.php/jchimp/article/view/29097)

We thank Dr. Rasmussen for his recent letter expressing concerns about statements made in our article with regard to the efficacy of sodium zirconium cyclosilicate (ZS-9) in patients with serum potassium (K +) concentrations \>6.5 mEq/L. Although ZS-9 is certainly one of the potential agents for the treatment of acute hyperkalemia in the future, the HARMONIZE trial ([@CIT0001]) was conducted in an outpatient setting and did not include hospitalized patients. Moreover as mentioned in our article ([@CIT0002]), the mean K+ level in the HARMONIZE trial was 5.6 mEq/L with only nine patients with baseline serum K+ \>6.5 mEq/L. While the substudy ([@CIT0003]) quoted by the authors showed a significant decline in the mean serum potassium level (0.4 and 0.6 mmol per liter at 1 and 2 hours, respectively), it had a mean baseline serum K+ of 6.3 mEq/L (95% CI -- 6.2--6.4). We do agree that due to the significant limitations of the existing treatment options, it is highly likely that ZS-9 with its low side-effect profile in the trials seems to be a viable alternative. However, large-scale randomized control trials looking at ZS-9 in the acute setting with severe hyperkalemia will be needed to implement it in clinical practice.
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